Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

Status Recruiting

Clinical Trial Summary

The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.

Clinical Trial Description

For years Fluorouracil was the established treatment for pancreatic cancer with median survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in comparison to Fluorouracil a significant better clinical benefit.

But after progression of the disease under a palliative first-line therapy there is no established second line therapy for pancreatic cancer.

So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy to get a reasonable second line concept. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00690300
Study type	Interventional
Source	University of Ulm
Contact	Thomas Seufferlein, Prof. Dr.
Phone	49-345-5572661
Email	thomas.seufferlein@medizin.uni-halle.de
Status	Recruiting
Phase	Phase 2
Start date	January 2008
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01774162` - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration	N/A
Completed	`NCT00930410` - Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor	N/A
Completed	`NCT00377936` - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas	Phase 2
Terminated	`NCT00198081` - Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)	Phase 2
Active, not recruiting	`NCT02905578` - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)	Phase 2
Completed	`NCT01446458` - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer	Phase 1
Recruiting	`NCT02789371` - Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions	N/A
Unknown status	`NCT00683358` - Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer	Phase 1/Phase 2
Terminated	`NCT00683085` - Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT03803930` - Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device	N/A
Completed	`NCT02681796` - Epidural Analgesia Use in Pancreatic Resections	Phase 1
Recruiting	`NCT02327065` - Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion	N/A
Completed	`NCT01693419` - S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer	Phase 2